Teva Pharmaceutical Industries stock: TD Cowen keeps Buy rating
Published on 11/16/2026 at 10:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst action and target
- TD Cowen analyst Joseph Thome reiterated a Buy rating on Teva on November 12, 2026.
- The analyst set a USD 57 price target, while TipRanks cited a Strong Buy consensus.
TD Cowen analyst Joseph Thome reiterated a Buy rating on Teva on November 12, 2026, and set a USD 57 price target. Markets Insider reported the analyst action on November 13.
Target stands above consensus
The report cited a Strong Buy consensus on Teva and an average analyst target of USD 51.61. TD Cowen's USD 57 target therefore sits above that cited average, adding a more bullish individual view to the current analyst picture.
The analyst action follows Teva's third-quarter results and its updated growth narrative, including stronger innovative-medicine brands and pipeline investments. The company has also outlined a long-term ambition to generate USD 6 billion to USD 7 billion in innovative-medicines revenue by 2030.
Teva Pharmaceutical Industries Ltd.
- Company: Teva Pharmaceutical Industries Ltd.
- ISIN: US8816242098
- Ticker: TEVA
U.S. equities provide the broader market setting for Teva stock through the S&P 500.
More news and analyses on Teva Pharmaceutical Industries stock
